RT112 Cell Line

Brief Introduction
Product List

General Information
Organism	Homo sapiens, human
Cell Line Description	RT-112 is a human bladder cancer cell line established in 1973 by Dr. Carol Rigby at St. Paul's Hospital, London, and first comprehensively described in the literature by F.J. Benham and colleagues in 1976. The cell line was derived from a surgically resected specimen of an untreated primary transitional cell carcinoma (histological grade G2) from an adult female patient. RT-112 cells exhibit an epithelioid morphology and grow as an adherent monolayer. In the fields of urologic oncology, molecular biology, and drug discovery, RT-112 is a globally recognized cornerstone model for the in vitro study of luminal-type bladder cancer. The cell line has garnered significant attention for harboring the endogenous FGFR3-TACC3 oncogenic fusion, making it a key model for investigating fibroblast growth factor receptor (FGFR) signaling pathways, evaluating selective small-molecule FGFR inhibitors, and analyzing mechanisms of chemotherapy resistance.
Tissue	Bladder
Cell Type	Epithelial cell
Population / Ancestry	Caucasian
Disease	Transitional Cell Carcinoma / Urothelial Carcinoma
Morphology	Epithelioid; growing in cohesive polygonal sheets
Gender	Female
Age	Unspecified
Product Format	Frozen
Growth Mode	Adherent
Biosafety Level	1 (Biosafety classification matches standard laboratory parameters for non-infectious human tumor cells)
Applications	1. A "gold standard" in vitro model for studying FGFR3-driven tumorigenesis, receptor dimerization, and the activation of downstream MAPK/ERK or PI3K/AKT/mTOR pathways; 2. A key target cell line for the preclinical evaluation of selective pan-FGFR inhibitors (e.g., Erdafitinib, Infigratinib) and combination therapy regimens; 3. Investigating the mechanisms underlying acquired chemotherapy resistance to standard-of-care treatments for bladder cancer (e.g., cisplatin, gemcitabine, and mitomycin C); 4. Studying epithelial differentiation markers (e.g., E-cadherin, α-, β-, and γ-catenin) and cellular stratification phenomena within urothelial biology; 5. Establishing robust subcutaneous, orthotopic, or organoid-based bladder cancer xenograft models in immunodeficient rodent models.
Shipped In	Dry ice
Storage Temperature	−196°C
Characteristics
Tumorigenic	Yes; highly tumorigenic in athymic nude mice, forming progressively expanding epithelial tumors.
Transformant	None; immortalized spontaneously from primary untreated transitional cell carcinoma tissue.
Oncogenic Drivers	FGFR3-TACC3 Gene Fusion. Harbors an intrachromosomal rearrangement on chromosome 4p16 that fuses the tyrosine kinase domain of FGFR3 in-frame to the transforming acidic coiled-coil 3 (TACC3) gene, resulting in permanent, ligand-independent receptor dimerization and signaling.
Karyotype	Human hyperdiploid karyotype with approximately 4% polyploidy. Modal chromosome number is 47 (ranges 44-47).
Mycoplasma Test	Negative
Culture Conditions and Handling
Subculturing	1. Completely remove and discard the complete culture medium from the culture vessel. 2. Gently rinse the cell monolayer with sterile, Ca2+/Mg2+-free PBS to neutralize residual serum components containing active trypsin inhibitors. 3. Add 1.0 to 2.5 mL of 0.25% trypsin-0.53 mM (0.03%) EDTA solution, pre-warmed to the appropriate temperature, ensuring the cell layer is completely covered. 4. Incubate at 37°C for 5 to 10 minutes, monitoring closely under an inverted microscope. Note: RT-112 cells exhibit strong intercellular adhesion and attachment; enzymatic treatment often requires up to 10 minutes for the cells to fully round up and detach into a single-cell suspension. 5. Add an equal volume of complete growth medium to rapidly terminate the enzymatic reaction. 6. Gently pipette the cell suspension up and down, centrifuge at approximately 300 × g for 3 to 5 minutes, carefully aspirate the supernatant, gently resuspend the cell pellet in fresh complete medium, and then distribute the cells into new culture vessels.
Thawing Protocol Note	RT-112 cells are sensitive to the initial alkalinity of the culture medium after thawing. Before adding the thawed cell suspension, the culture vessel containing fresh complete growth medium should be placed in a 5% CO2 incubator for at least 15 minutes to allow the medium's pH to reach the normal physiological range (7.0 to 7.6).
Medium Renewal	2 to 3 times per week
Subcultivation Ratio	Split confluent cultures (70-80% density) at a standard ratio of 1:2 to 1:6. To maintain optimal proliferative kinetics, split the culture before it reaches 100% density.
Culture Conditions	Atmosphere: Air, 95%; CO2, 5%; Temperature: 37°C
Cryopreservation	90% Complete culture growth medium + 10% DMSO (or 50% Basal medium + 40% FBS + 10% DMSO)

Cat.No.	Product Name	Price
CSC-RR0352	GFP Reporter Cell Line - RT-112	Inquiry
CSC-RR0644	Luciferase Reporter Cell Line - RT112	Inquiry
CSC-RO01551	OVAL Stable Cell Line - RT-112	Inquiry
CSC-RO01646	OVAL Stable Cell Line - RT112	Inquiry
CSC-RO01804	GFP/OVAL Stable Cell Line - RT-112	Inquiry
CSC-RO01899	GFP/OVAL Stable Cell Line - RT112	Inquiry
CSC-RO02057	Luc/OVAL Stable Cell Line - RT-112	Inquiry
CSC-RO02152	Luc/OVAL Stable Cell Line - RT112	Inquiry
CSC-RO02310	GFP/Luc/OVAL Stable Cell Line - RT-112	Inquiry
CSC-RO02405	GFP/Luc/OVAL Stable Cell Line - RT112	Inquiry

The above is only part of a part of cell line products. If you don't find the cell line you want, Creative Biogene can also provide stable cell line generation service with the best prices and fastest turnaround time for you! Contact us for more information or to request a quote.

* For research use only. Not intended for any clinical use.

Quick Inquiry